Roche Türkiye
Roche Türkiye is the Turkish affiliate of Roche Group, selling innovative pharmaceuticals across six therapeutic areas and in vitro diagnostics (including the Accu-Chek diabetes brand) to hospitals, clinics, physicians, and clinical laboratories across Turkey via direct sales, pharmacy distribution, and laboratory supply channels.
- Company typePrivate
- Founded1896
- Headquartersİstanbul, Türkiye
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Roche Türkiye does
Roche Türkiye is the Turkish affiliate of the global Roche Group (F. Hoffmann-La Roche Ltd, publicly traded on the SIX Swiss Exchange), operating through two Istanbul-based corporate entities: Roche Müstahzarları Sanayi A.Ş. for pharmaceuticals and Roche Diagnostics Turkey A.Ş. for in vitro diagnostics. Founded in Turkey in 1958 and employing approximately 190 people, the company sells innovative medicines across six therapeutic areas — respiratory diseases, hematology, neurology, oncology, rheumatology, and ophthalmology — and a comprehensive diagnostics portfolio spanning women's health, cardiology, infectious diseases, pathology, oncology, and diabetes management through the Accu-Chek brand.
The technology stack combines therapeutic biologics and small molecules with in vitro diagnostic systems, including high-sensitivity cardiac troponin T and NT-proBNP biomarkers, HPV testing, automated digital pathology scoring, and tissue staining workflows. The parent group's Institute of Human Biology in Basel develops 2D/3D human tissue and organ miniatures from stem cells for drug discovery, supporting personalized healthcare positioning. The diagnostics side supplies instruments and reagents directly to clinical laboratories, while pharmaceuticals flow through pharmacy networks and direct hospital sales across Turkey.
Revenue is generated through one-time pharmaceutical sales, hardware and consumable sales in diagnostics, and professional services including medical education and clinical support. Pricing is negotiated privately with healthcare institutions and insurers and is not publicly disclosed. Go-to-market relies on enterprise field sales targeting specialists (oncologists, cardiologists, neurologists), complemented by medical congress participation, university clinical research collaborations (notably with İnönü University), and physician engagement platforms such as Medikaynak. Customer segments are hospitals, clinics, physicians, clinical laboratories, and ultimately patients across Turkey, served under ISO 9001, ISO 27001, GDPR, and Turkey's KVKK compliance frameworks.
Roche Türkiye firmographics
Firmographics- Name
- Roche Türkiye
- Legal name
- Roche Müstahzarları Sanayi Anonim Şirketi ve Roche Diagnostics Turkey Anonim Şirketi
- Website
- https://roche.com.tr
- Company type
- Private
- Founded year
- 1896
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Roche Türkiye is the Turkish affiliate of Roche Group, selling innovative pharmaceuticals across six therapeutic areas and in vitro diagnostics (including the Accu-Chek diabetes brand) to hospitals, clinics, physicians, and clinical laboratories across Turkey via direct sales, pharmacy distribution, and laboratory supply channels.
- Ownership category
- akta.pro rank
Roche Türkiye industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Roche Türkiye is headquartered
LocationHeadquarters
- HQ city
- İstanbul
- HQ country
- Türkiye
- HQ region
- Europe
Offices2 records
Markets served
Roche Türkiye business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Pharmaceutical Products: Sale of innovative medicines for treatment of chronic and life-threatening diseases including respiratory, hematology, neurology, oncology, rheumatology, and ophthalmology conditions.
- Diagnostic Solutions: Sale and distribution of in vitro diagnostic products and solutions including tests for infectious diseases, cardiology, oncology, women's health, and diabetes management.
- Professional Services: Medical education, training, and clinical support services provided to healthcare professionals and institutions.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Roche Türkiye product offering
Product offeringCore offering
Roche Türkiye operates as the Turkish subsidiary of the global Roche Group, selling innovative pharmaceutical medicines across six therapeutic areas (respiratory, hematology, neurology, oncology, rheumatology, ophthalmology) and providing in vitro diagnostic solutions spanning women's health, cardiology, infectious diseases, pathology, oncology, and diabetes care through the Accu-Chek brand. The company distributes products directly to hospitals, clinics, physicians, and clinical laboratories across Turkey under two legal entities: Roche Müstahzarları Sanayi A.Ş. (pharmaceuticals) and Roche Diagnostics Turkey A.Ş. (diagnostics).
Product overview
Roche Türkiye operates two distinct entities: Roche Müstahzarları Sanayi A.Ş. (pharmaceuticals) and Roche Diagnostics Turkey A.Ş. (diagnostics). The pharmaceutical division offers treatment solutions across six therapeutic areas: Respiratory Diseases, Hematology, Neurology, Oncology, Rheumatology, and Ophthalmology. The diagnostics division provides in vitro diagnostic solutions covering Women's Health, Cardiology, Infectious Diseases, Pathology, and Oncology diagnostics, along with the Accu-Chek diabetes care brand. The company also conducts research through the Institute of Human Biology in Basel. Employee benefits include flexible work programs (RocheFlex/Roche Vitrin), education support, and language training.
Differentiator
Problem solved
Functional benefit
Brands
- Accu-Chek: Diabetes care brand offering blood glucose monitoring solutions and products for diabetes management.
Products and services
- Respiratory Diseases Treatment Solutions
- Hematology Treatment Solutions
- Neurology Treatment Solutions
- Oncology Treatment Solutions
- Rheumatology Treatment Solutions
- Ophthalmology Treatment Solutions
- Women's Health Diagnostics
- Cardiology Diagnostics
- Infectious Diseases Diagnostics
- Pathology Diagnostics
- Oncology Diagnostics
- Accu-Chek Diabetes Care
Quantifiable outcome
- Over 30 Roche drugs are listed in WHO Essential Medicines List
- +2 more outcomes
Companies that use Roche Türkiye
Customer profileSegments3 records
Ideal customer profiles3 records
Roche Türkiye technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Roche Türkiye partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- İnönü Üniversitesi (Inönü University)coreRoche Türkiye and İnönü University collaboration established the Clinical Research and Center of Excellence Application and Research Center Support Unit following the 2023 Kahramanmaraş earthquakes. The partnership aims to strengthen healthcare infrastructure and clinical research capabilities in Turkey.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Roche Türkiye competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Roche Türkiye social profiles
Digital presenceRoche Türkiye compliance and trust
Trust signalCompliance3 records
Roche Türkiye financial estimates
Financial estimateRevenue estimate
Valuation estimate
Roche Türkiye leadership team
Management profileNumber of profiles
Profiles3 records
Roche Türkiye funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Roche Türkiye M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Roche Türkiye
What does Roche Türkiye do?
Roche Türkiye operates as the Turkish subsidiary of the global Roche Group, selling innovative pharmaceutical medicines across six therapeutic areas (respiratory, hematology, neurology, oncology, rheumatology, ophthalmology) and providing in vitro diagnostic solutions spanning women's health, cardiology, infectious diseases, pathology, oncology, and diabetes care through the Accu-Chek brand. The company distributes products directly to hospitals, clinics, physicians, and clinical laboratories across Turkey under two legal entities: Roche Müstahzarları Sanayi A.Ş. (pharmaceuticals) and Roche Diagnostics Turkey A.Ş. (diagnostics).
Is Roche Türkiye a public or private company?
Roche Türkiye is a private company. It is classified as corporate owned and is currently operating.
When was Roche Türkiye founded?
Roche Türkiye was founded in 1896. It employs 101 to 250 people.
Where is Roche Türkiye based?
Roche Türkiye is headquartered in İstanbul, Türkiye, in the Europe region.
How does Roche Türkiye make money?
Three revenue lines are on record. Pharmaceutical Products are the primary driver. The others are diagnostic Solutions and professional Services.
Does Roche Türkiye have an API?
No public API is recorded for Roche Türkiye.
What industry is Roche Türkiye in?
Roche Türkiye's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.